DailyDoctor Archive Specialties Get app
All ophthalmology briefings

The edition · Ophthalmology

One intravitreal bevacizumab dose kept trabeculectomies working at three years

A double-masked trial found a single intraoperative injection alongside mitomycin C improved trabeculectomy survival to 36 months. Also: PAMM on OCT separates giant cell arteritis from NAION, phaco-GATT against phacotrabeculectomy, and HOTV charts for preschool screening.

The edition in brief

A single-centre, double-masked, placebo-controlled trial randomised 131 patients having trabeculectomy or phacotrabeculectomy with mitomycin C to one intravitreal bevacizumab 1.25 mg injection or saline. At 36 months, with 85% follow-up, surgical survival was higher with bevacizumab (hazard ratio for complete success failure 0.17) and fewer eyes needed drops. A retrospective neuro-ophthalmology study found paracentral acute middle maculopathy on OCT in 28% of 80 biopsy-proven giant cell arteritis patients and none of 179 with non-arteritic ischaemic optic neuropathy, including in patients without visual symptoms and after steroids. A non-randomised Indian study of 152 eyes found phaco-GATT and phacotrabeculectomy gave similar one-year pressure reduction and medication freedom, with more hyphaema after GATT and hypotony after trabeculectomy. A Shanghai study of 995 children tested both charts in random order and found HOTV gave better acuity and fewer false referrals than tumbling E in preschool children, with the gap closing by age 8.

In this edition

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free